In one of our previous issues, we wrote about investigations into opioid manufacturers’ marketing and sales tactics by state attorneys general. These investigations were prompted by what has been described as an opioid epidemic due to the rapid increase in the use of prescription and non-prescription opioids since 2010. Opiates are a class of strong painkillers or analgesic drugs, including those naturally derived from opium, such as morphine and heroin.
On July 6, 2017, Endo International PLC (Endo) pulled its painkiller Opana ER from the market, following pressure from the U.S. Food and Drug Administration (FDA) to stop sales of the abuse-linked drug and as prescriptions of opioids remain high in many parts of the country. The FDA requested that the drugmaker withdraw the prescription opioid due to abuse risks. The FDA has said that it is examining abuse patterns involving other opioids and will take further action if appropriate.
Endo’s decision to comply with the FDA’s request may also have been pushed by the threat of litigation. As noted in our previous report, the number of suits alleging that drug makers have downplayed the addictive risks of their painkillers, filed largely by states and other municipalities, has grown significantly in recent months.
In March of 2016, the Centers for Disease Control and Prevention (CDC) released new guidelines for prescribing opioids, asking primary care providers to consider alternatives to prescription painkillers, limit the length of treatment and monitor patients to see if opioids are indeed the right choice for them. While voluntary, those guidelines were prompted to reduce opioid overdose deaths.
Per the CDC, the areas with highest prescribing rates of opioids also share qualities like higher unemployment and a greater prevalence of diabetes and arthritis, and they tend to be small cities and large towns.
If you would like more information about these cases, you can contact Rhon Jones in our Toxic Torts Section. Rhon can be reached at 800-898-2034 or by email at Rhon.Jones@beasleyallen.com.
Contact us today for a free legal consultation with an experienced attorney.
Fields marked *may be required for submission.
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.